Compounds > 9-deazahypoxanthine
Page last updated: 2024-10-15

9-deazahypoxanthine

Description

9-deazahypoxanthine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135488881
CHEMBL ID1230671
SCHEMBL ID1056425
SCHEMBL ID1056424
MeSH IDM0584321

Synonyms (53)

Synonym
BB 0261004
CHEMBL1230671
1h,4h,5h-pyrrolo[3,2-d]pyrimidin-4-one
9HX ,
9-deazahypoxanthine
1I80
DB04095
5655-01-6
3h-pyrrolo[3,2-d]pyrimidin-4(5h)-one
AKOS000265724
1,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
5h-pyrrolo[3,2-d]pyrimidin-4-ol
AKOS015918379
1h-pyrrolo[3,2-d]pyrimidin-4(5h)-one
AKOS006342700
FT-0647791
AM20100041
AM20100393
PB28030
AB2818
39455-99-7
1h-pyrrolo[3,2-d]pyrimidin-4-ol
3h,5h-pyrrolo[3,2-d]pyrimidin-4-one
3h,5h-pyrrolo[3,2-d]pyrimidin-4one
3h,4h,5h-pyrrolo[3,2-d]pyrimidin-4-one
3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
CS-M1569
SCHEMBL1056425
SCHEMBL1056424
3,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one #
3,5-dihydropyrrolo(3,2-d)pyrimidin-4-one
3,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
DS-0320
4h-pyrrolo[3,2-d]pyrimidin-4-one, 1,5-dihydro-
3h-pyrrolo[3,2-d]pyrimidin-4-ol
mfcd09832196
J-511337
4-hydroxypyrrolo-[3,2-d]pyrimidine
1357580-90-5
FT-0731102
BCP28322
mfcd09037890
SY013436
AMY7765
DTXSID60971989
1,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one; 3h-pyrrolo[3,2-d]pyrimidin-4(5h)-one
Q27457017
D87033
CS-0332452
EN300-102659
PD059389
Z1198184375
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, PURINE NUCLEOSIDE PHOSPHORYLASEMycobacterium tuberculosisKd0.39000.39000.39000.3900AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2001Biochemistry, Jul-27, Volume: 40, Issue:28
Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with immucillin-H and its pieces.
AID1811Experimentally measured binding affinity data derived from PDB2001Biochemistry, Jul-27, Volume: 40, Issue:28
Structures of purine nucleoside phosphorylase from Mycobacterium tuberculosis in complexes with immucillin-H and its pieces.
AID445467Displacement of [3H]adenine from adenine 1 receptor in rat brain cortical membrane by liquid scintillation counting2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.
AID445468Inhibition of [3H]adenine binding to adenine 1 receptor in rat brain cortical membrane at 100 uM by liquid scintillation counting2009Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's6 (60.00)24.3611
2020's2 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		2.05106-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2-chloroadenosine
5-chloroformycin A: structure given in first source		2.0510purine nucleoside
2'-deoxyadenosine
2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source		2.0510purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
9-benzyladenine
[no description available]		2.0510
cladribine
[no description available]		2.0510organochlorine compound;
purine 2'-deoxyribonucleoside		antineoplastic agent;
immunosuppressive agent
6-n-hydroxylaminopurine
N(6)-hydroxyadenine : A member of the class of 6-aminopurinnes that is adenine in which one of the exocyclic amino hydrogens is replaced by a hydroxy group.		2.05106-aminopurines;
hydroxylamines;
nucleobase analogue		mutagen;
teratogenic agent
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.5220copper group element atom;
elemental gold
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		2.9630divalent inorganic anion;
phosphite ion
3-deazaadenine
[no description available]		2.0510
8-hydroxyadenine
8-hydroxyadenine: xanthine oxidase reacted adenine metabolite in epidermis of hairless mice; structure. 8-oxoadenine : An oxopurine that is adenine bearing a single oxo substituent at position 8.. 8-hydroxyadenine : A nucleobase analogue that is adenine bearing a single hydroxy substituent at position 8.		2.05106-aminopurines;
heteroaryl hydroxy compound;
nucleobase analogue;
oxopurine		bacterial metabolite;
human metabolite
7-deazaadenine
[no description available]		2.0510
n(6)-cyclohexyladenosine
N(6)-cyclohexyladenosine: structure given in first source; receptors, purinergic P1 agonist		2.0510
guanine
[no description available]		7.13102-aminopurines;
oxopurine;
purine nucleobase		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
forodesine
forodesine: structure in first source		210dihydroxypyrrolidine;
pyrrolopyrimidine
9-deazaguanine
[no description available]		7.1310
ConditionIndicatedRelationship StrengthStudiesTrials
Anaplastic Astrocytoma
[description not available]		02.0510
Astrocytoma
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)		02.0510
Cholera Infantum
[description not available]		02.3110
Infections, Helicobacter
[description not available]		02.3110
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		02.3110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.110
Anasarca
[description not available]		02.110
Innate Inflammatory Response
[description not available]		02.110
Benign Neoplasms
[description not available]		02.110
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.110